<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739102</url>
  </required_header>
  <id_info>
    <org_study_id>P05-6201</org_study_id>
    <nct_id>NCT00739102</nct_id>
  </id_info>
  <brief_title>S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease</brief_title>
  <acronym>STROLL</acronym>
  <official_title>S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, non-randomized, single-arm, prospective trial evaluating the safety and
      effectiveness of the S.M.A.R.T.™ Nitinol Stent System implantation in approximately 250
      patients with obstructive superficial femoral artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month Primary Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis &gt;50% with a peak systolic velocity ratio &gt;2.0 as measured by Duplex ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Primary safety endpoint is defined as the rate of freedom from all causes of death, index limb amputation, and clinically driven target lesion revascularization (TLR) through 30 days. A clinically driven TLR is any intervention in the stented target lesion following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise ABI ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target lesion with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death Rate at 30-day Post Procedure</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Limb Amputation at 30-day Follow up</measure>
    <time_frame>30 day</time_frame>
    <description>Index Limb Amputation is defined as surgical removal of all or part of the lower extremity from the toe up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven Target Vessel Revascularization (TVR) at 30-day Post Procedure</measure>
    <time_frame>30 days</time_frame>
    <description>A clinically driven TVR is any intervention of the target vessel following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise Ankle-Brachial Index (ABI) ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target vessel with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Driven Target Vessel Revascularization (TVR) at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>A clinically driven TVR is any intervention of the target vessel following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise Ankle-Brachial Index (ABI) ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target vessel with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Fracture at 12-month Follow Up</measure>
    <time_frame>12 months</time_frame>
    <description>Stent fracture was assessed by x-ray evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 6-month Follow up</measure>
    <time_frame>6 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 12-month Follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford/Becker Classification at 30-day Follow Up</measure>
    <time_frame>30 days</time_frame>
    <description>The Rutherford/Becker Classification is a commonly used clinical staging system which allows clinicians to describe and discuss patients with peripheral artery disease. The classification has seven stages as follows:
Stage 0 - Asymptomatic, no hemodynamically significant occlusive disease
Stage 1 - Mild claudication
Stage 2 - Moderate claudication
Stage 3 - Severe claudication
Stage 4 - Ischemic rest pain
Stage 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia
Stage 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford / Becker Classification Category at 12-month Follow Up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven TLR, and significant embolic events, which were defined as causing end-organ damage.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Superficial Femoral Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S.M.A.R.T.® Nitinol Self-Expandable Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>S.M.A.R.T. ® Stent</intervention_name>
    <description>The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 30 years

          -  For women of child bearing potential, a pregnancy test within 7 days prior to index
             procedure (the test results must be negative to be eligible).

          -  Symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4) with
             a resting or exercise ABI &lt;/= 0.8.

          -  A single superficial femoral artery lesion with &gt; 50% stenosis or total occlusion.

          -  Stenotic lesion or occluded length within the same vessel (one long or multiple serial
             lesions) &gt;/= 4.0 cm to &lt;/= 15.0 cm, by visual estimate. The stenosis must be treatable
             with no more than two stents, minimizing the stent overlap whose combined length &lt;/=
             170 mm.

          -  Reference vessel diameter (RVD) &gt;/= 4.0 mm and &lt;/= 6.0 mm by visual assessment.

          -  All lesions are to be located at least three centimeters proximal to the superior edge
             of the patella.

          -  Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with
             at least one of three vessels patent (&lt; 50% stenosis) to the ankle or foot.

          -  The guidewire is across the target lesion(s) and located intraluminally within the
             distal vessel.

          -  Poor aortoiliac or common femoral &quot;inflow&quot; (i.e. angiographically defined &gt; 50%
             stenosis of the iliac or common femoral artery) that would be deemed inadequate to
             support a femoropopliteal bypass graft must be successfully treated prior to treatment
             of the target lesion. This can be done just prior to treatment of the target lesion.
             Successful treatment is defined as &lt;30% stenosis after either PTA or stenting of the
             inflow lesion. After treatment of the inflow lesion, if the peak to peak pressure
             gradient across the inflow lesion is &lt;/= 20mmHg and the peak to peak pressure gradient
             across the SFA target lesion is &gt;/= 20mmHg, then the patient will be included in the
             study.

          -  A patient with bilateral obstructive SFA disease is eligible for enrollment into the
             study.

          -  Eligibility for standard surgical repair, if necessary.

          -  A patient who requires a coronary intervention, should have it performed at least 7
             days prior to the treatment of the target lesion.

          -  Patient or authorized representative must provide written informed consent and written
             HIPAA authorization prior to initiation of study procedures.

          -  Patient must be willing to comply with the specified follow-up evaluation schedule.

        Exclusion Criteria:

          -  Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days.

          -  Receiving dialysis or immunosuppressant therapy.

          -  Thrombolysis of the target vessel within 72 hours prior to the index procedure where
             complete resolution of the thrombus was not achieved.

          -  Recent stroke within past 90 days.

          -  Femoral, iliac or aortic aneurysm or aneurysm in the SFA or popliteal artery within
             past 5 years.

          -  Required stent placement via a popliteal approach.

          -  Required stent placement across or within 0.5 cm of the SFA / PFA bifurcation.

          -  Procedures which are pre-determined to require stent-in-stent placement to obtain
             patency, such as severe calcification which is resistant to stenting, or for in-stent
             restenosis.

          -  Significant vessel tortuosity or other parameters prohibiting access to the lesion or
             90° tortuosity which would prevent delivery of the stent device.

          -  Previously deployed stent within the SFA of the target limb.

          -  Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or
             ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot
             be medically managed.

          -  Presence of thrombus prior to crossing the lesion

          -  Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6)

          -  Serum creatinine level &gt;/= 2.5 mg/dl at time of screening visit

          -  Known or suspected active infection at the time of the procedure

          -  Bleeding diathesis

          -  Presence of an aortic, iliac or femoral artificial graft

          -  Life expectancy less than one year, or any other factors preventing clinical followup.

          -  Use of cryoplasty, laser, or atherectomy devices on the target vessel at the time of
             index procedure

          -  In-stent restenotic lesions at time of procedures.

          -  Restenotic lesion that had previously been treated by atherectomy, laser, or
             cryoplasty within 90 days of the index procedure.

          -  Patient is unwilling or unable to comply with procedures specified in the protocol or
             has difficulty or inability to return for follow-up visits as specified by the
             protocol.

          -  Patient is known to be pregnant, incarcerated, mentally incompetent, and/or alcohol or
             drug abuser.

          -  Patient is currently participating in any other investigational drug or medical device
             study that has not completed primary endpoint(s) evaluation or clinically interferes
             with the endpoints from this study or future participation in such studies prior to
             the completion of this study.

          -  Patient has had major surgical or interventional procedures unrelated to this study
             within 30 days prior to this study or planned surgical or interventional procedures
             within 30 days of entry into this study. Interventional procedures performed to the
             ipsilateral iliac artery to provide access will be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Gray, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <results_first_submitted>July 8, 2013</results_first_submitted>
  <results_first_submitted_qc>September 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 18, 2013</results_first_posted>
  <disposition_first_submitted>November 11, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 11, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 16, 2009</disposition_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial Femoral Artery</keyword>
  <keyword>Nitinol Self-Expandable Stent System</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 250 patients were enrolled from August 14, 2008 to March 15, 2010 across 39 clinical sites in the U.S.</recruitment_details>
      <pre_assignment_details>This is a multi-center, non-randomized, single-arm, prospective trial. Patients were eligible for enrollment if they met all inclusion criteria and none of the exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>S.M.A.R.T.® Nitinol Stent System</title>
          <description>The Cordis S.M.A.R.T. ®Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="235">Completed 12-Month Follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent-To-Treat (ITT) Population</population>
      <group_list>
        <group group_id="B1">
          <title>S.M.A.R.T.™ Nitinol Stent System</title>
          <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.71" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle Eastern</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12-month Primary Patency Rate</title>
        <description>Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis &gt;50% with a peak systolic velocity ratio &gt;2.0 as measured by Duplex ultrasound.</description>
        <time_frame>12 months</time_frame>
        <population>As a subset of the modified ITT, this analysis population consisted of the subjects who had ultrasound assessment at 12 months or had target vessel revascularization (TVR) performed by 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>12-month Primary Patency Rate</title>
          <description>Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis &gt;50% with a peak systolic velocity ratio &gt;2.0 as measured by Duplex ultrasound.</description>
          <population>As a subset of the modified ITT, this analysis population consisted of the subjects who had ultrasound assessment at 12 months or had target vessel revascularization (TVR) performed by 12 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects Achieved Primary Patency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" lower_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects Didn't Achieve Primary Patency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis to be tested was Ho: P = 0.66 against Ha: P &gt; 0.66, where 0.66 was the Objective Performance Criteria (OPC). A sample size of 212 subjects was required to achieve 90% power to reject the 66% 12-months patency rate at a one-sided 2.5% significance level when the unknown true patency is at 76%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.437</p_value>
            <p_value_desc>The observed rate of primary patency at 12 month was 66.5% (143/215) with a lower 95% confidence interval of 60.0%.</p_value_desc>
            <method>Agresti-Coull method</method>
            <param_type>Proportion - 12-month patency rate</param_type>
            <param_value>0.665</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>0.725</ci_upper_limit>
            <estimate_desc>The 95% confidence intervals and the standard error were calculated using the Agresti-Coull method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Rate at 30-day Post Procedure</title>
        <time_frame>30 days</time_frame>
        <population>Active subjects in the Modified ITT population at 30-day post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Death Rate at 30-day Post Procedure</title>
          <population>Active subjects in the Modified ITT population at 30-day post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death at 12-month Post Procedure</title>
        <time_frame>12 months</time_frame>
        <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Death at 12-month Post Procedure</title>
          <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Death Rate (%)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index Limb Amputation at 30-day Follow up</title>
        <description>Index Limb Amputation is defined as surgical removal of all or part of the lower extremity from the toe up.</description>
        <time_frame>30 day</time_frame>
        <population>Active subjects in the Modified ITT population at 30 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Index Limb Amputation at 30-day Follow up</title>
          <description>Index Limb Amputation is defined as surgical removal of all or part of the lower extremity from the toe up.</description>
          <population>Active subjects in the Modified ITT population at 30 days post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Index Limb Amputation Rate (%)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Driven Target Vessel Revascularization (TVR) at 30-day Post Procedure</title>
        <description>A clinically driven TVR is any intervention of the target vessel following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise Ankle-Brachial Index (ABI) ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target vessel with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
        <time_frame>30 days</time_frame>
        <population>Active subjects in the Modified ITT population at 30-day post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven Target Vessel Revascularization (TVR) at 30-day Post Procedure</title>
          <description>A clinically driven TVR is any intervention of the target vessel following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise Ankle-Brachial Index (ABI) ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target vessel with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
          <population>Active subjects in the Modified ITT population at 30-day post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinically Driven TVR Rate (%)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Driven Target Vessel Revascularization (TVR) at 12-month Post Procedure</title>
        <description>A clinically driven TVR is any intervention of the target vessel following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise Ankle-Brachial Index (ABI) ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target vessel with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
        <time_frame>12 months</time_frame>
        <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Driven Target Vessel Revascularization (TVR) at 12-month Post Procedure</title>
          <description>A clinically driven TVR is any intervention of the target vessel following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise Ankle-Brachial Index (ABI) ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target vessel with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
          <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinically Driven TVR Rate (%)</param_type>
            <param_value>13.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Fracture at 12-month Follow Up</title>
        <description>Stent fracture was assessed by x-ray evaluation.</description>
        <time_frame>12 months</time_frame>
        <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Fracture at 12-month Follow Up</title>
          <description>Stent fracture was assessed by x-ray evaluation.</description>
          <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Stent Fracture Rate (%)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index Limb Ischemia at 6-month Follow up</title>
        <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
        <time_frame>6 months</time_frame>
        <population>Active subjects in the Modified ITT population at 6-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Index Limb Ischemia at 6-month Follow up</title>
          <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
          <population>Active subjects in the Modified ITT population at 6-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Index Limb Ischemia Rate (%)</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint</title>
        <description>Primary safety endpoint is defined as the rate of freedom from all causes of death, index limb amputation, and clinically driven target lesion revascularization (TLR) through 30 days. A clinically driven TLR is any intervention in the stented target lesion following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise ABI ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target lesion with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
        <time_frame>30 days</time_frame>
        <population>Active subjects in the Modified ITT population at 30 days post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint</title>
          <description>Primary safety endpoint is defined as the rate of freedom from all causes of death, index limb amputation, and clinically driven target lesion revascularization (TLR) through 30 days. A clinically driven TLR is any intervention in the stented target lesion following documented recurrent symptomatic leg ischemia by Rutherford/Becker Classification (category 2, 3 or 4), with a resting or exercise ABI ≤ 0.8 and &gt;50% diameter in-lesion stenosis by angiography. Revascularization of a target lesion with an in-lesion diameter stenosis of &gt;70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms, will also be considered clinically driven.</description>
          <population>Active subjects in the Modified ITT population at 30 days post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects Achieved Primary Safety Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects Didn't Achieve Primary Safety Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis to be tested was Ho: P = 0.88 against Ha: P &gt; 0.88, where 0.88 was the Objective Performance Criteria (OPC).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Agresti-Coull method</method>
            <param_type>Primary safety endpoint rate (%)</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.2</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index Limb Ischemia at 12-month Follow up</title>
        <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
        <time_frame>12 months</time_frame>
        <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Index Limb Ischemia at 12-month Follow up</title>
          <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
          <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Index Limb Ischemia Rate (%)</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rutherford/Becker Classification at 30-day Follow Up</title>
        <description>The Rutherford/Becker Classification is a commonly used clinical staging system which allows clinicians to describe and discuss patients with peripheral artery disease. The classification has seven stages as follows:
Stage 0 – Asymptomatic, no hemodynamically significant occlusive disease
Stage 1 – Mild claudication
Stage 2 – Moderate claudication
Stage 3 – Severe claudication
Stage 4 – Ischemic rest pain
Stage 5 – Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia
Stage 6 – Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable</description>
        <time_frame>30 days</time_frame>
        <population>Active subjects in the Modified ITT population at 30-day post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Rutherford/Becker Classification at 30-day Follow Up</title>
          <description>The Rutherford/Becker Classification is a commonly used clinical staging system which allows clinicians to describe and discuss patients with peripheral artery disease. The classification has seven stages as follows:
Stage 0 – Asymptomatic, no hemodynamically significant occlusive disease
Stage 1 – Mild claudication
Stage 2 – Moderate claudication
Stage 3 – Severe claudication
Stage 4 – Ischemic rest pain
Stage 5 – Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia
Stage 6 – Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable</description>
          <population>Active subjects in the Modified ITT population at 30-day post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rutherford/Becker Classification - 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rutherford / Becker Classification Category at 12-month Follow Up</title>
        <time_frame>12 months</time_frame>
        <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Rutherford / Becker Classification Category at 12-month Follow Up</title>
          <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rutherford/Becker Classification - 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rutherford/Becker Classification - 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Events at 12-month Post Procedure</title>
        <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven TLR, and significant embolic events, which were defined as causing end-organ damage.</description>
        <time_frame>12 months</time_frame>
        <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
        <group_list>
          <group group_id="O1">
            <title>S.M.A.R.T.™ Nitinol Stent System</title>
            <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Events at 12-month Post Procedure</title>
          <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven TLR, and significant embolic events, which were defined as causing end-organ damage.</description>
          <population>Active subjects in the Modified ITT population at 12-month post procedure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Major adverse event rate (%)</param_type>
            <param_value>14.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.2</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>S.M.A.R.T.™ Nitinol Stent System</title>
          <description>The Cordis S.M.A.R.T.™ Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>In-stent arterial restenosis</sub_title>
                <counts group_id="E1" events="56" subjects_affected="48" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="250"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patricia Schleckser, Director Medical Affairs</name_or_title>
      <organization>Cordis Corporation, a Johnson &amp; Johnson company</organization>
      <phone>908-541-4564</phone>
      <email>pschleck@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

